Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 65
Summary
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Retrospective
Participation Requirements
- Age
- Between 2 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04285723
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals